Omeros Beats Q3 Estimates as YARTEMLEA Sales Rise
Omeros reported third-quarter 2026 earnings of $0.06 per share, beating the consensus estimate of a loss of $0.05 per share and improving on a loss of $0.19 per share a year earlier. Sales of its transplant complication treatment YARTEMLEA rose year over year.
The company recorded a second consecutive quarter of positive operating cash flow, but a non-cash adjustment related to its convertible notes pushed it to a net loss for the period.
The quarter marks a swing from the company's recent full-year results: in fiscal 2025, Omeros reported a net loss of 3.4 million USD and diluted EPS of -0.05 USD.
Important questions to consider
Omeros posted quarterly earnings of $0.06 per share, while the consensus estimate had pointed to a loss of $0.05 per share. A year earlier, the company reported a loss of $0.19 per share.
The company said a non-cash adjustment tied to its convertible notes pushed it to a net loss for the quarter. That charge came even as sales of YARTEMLEA rose and operating cash flow was positive.
Higher third-quarter sales of YARTEMLEA, its treatment for a transplant complication, drove the top line. The company also recorded a second consecutive quarter of positive operating cash flow.
Sources
- Omeros Q3 Earnings Call Highlights
MarketBeat
- Omeros Corporation (OMER) Q3 2026 Earnings Call Transcript
Seeking Alpha
- Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
Zacks Investment Research